MaxCyte director granted RSUs and options

MAXCYTE, INC. director Patrick J. Balthrop received equity-based compensation in the form of restricted stock units and stock options.

Rhea-AI Filing Summary

MAXCYTE, INC. director Patrick J. Balthrop received equity-based compensation in the form of restricted stock units and stock options. He was granted 30,421 RSUs, each representing one share of common stock, and 49,579 stock options with an exercise price of $1.13 per share. The RSU grant was made under the company’s equity grant policy for non-employee directors and is scheduled to vest on June 17, 2027, contingent on his continued service. Following the RSU grant, Balthrop directly holds 80,998 shares of common stock. The stock options, which are also directly held, are exercisable into 49,579 shares of common stock and are scheduled to expire on June 16, 2036.

Insider Trade Summary

Grant/Award: 80,000 shares

Grant/Award 2 txns

Insider BALTHROP PATRICK J

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	49,579	$0.00	$0.00
Grant/Award	Common Stock	30,421	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 49,579 contracts (Direct); Common Stock — 80,998 shares (Direct)

Footnotes (2)

1. F1. These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
2. F2. This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 17, 2027, subject to the reporting person's continuous service as of such vesting date.

Key Figures

RSU grant: 30,421 RSUs Shares held after grant: 80,998 shares Stock options granted: 49,579 options +3 more

6 metrics

RSU grant 30,421 RSUs Restricted stock units granted June 17, 2026

Shares held after grant 80,998 shares Common stock directly held after RSU grant

Stock options granted 49,579 options Options on common stock granted June 17, 2026

Option exercise price $1.13 per share Stock option conversion or exercise price

Option expiration June 16, 2036 Stock option expiration date

RSU vesting date June 17, 2027 RSUs vest subject to continuous service

Key Terms

restricted stock units ("RSUs"), Equity Grant Policy, non-employee directors, Stock Option (right to buy)

4 terms

restricted stock units ("RSUs") financial

"These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right..."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

Equity Grant Policy financial

"This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors."

non-employee directors financial

"This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors."

Non-employee directors are board members who do not work for the company as salaried employees and usually do not hold day-to-day management roles. They act like outside referees or independent coaches, providing oversight, asking tough questions, and protecting shareholders’ interests; investors care because these directors help ensure management is accountable, reduce conflicts of interest, and influence decisions that affect company strategy and long-term value.

Stock Option (right to buy) financial

"Stock Option (right to buy) listed as a derivative security transaction."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did MXCT director Patrick J. Balthrop receive?

Patrick J. Balthrop received a grant of 30,421 restricted stock units and 49,579 stock options. Each RSU represents one share of MaxCyte common stock, while the options allow him to buy shares at a fixed $1.13 exercise price.

How many MXCT shares does Patrick J. Balthrop hold after this Form 4?

After the reported grant, Patrick J. Balthrop directly holds 80,998 shares of MaxCyte common stock. This total reflects his position following the award of 30,421 restricted stock units reported in the non-derivative section of the Form 4.

What are the terms of Patrick J. Balthrop’s MaxCyte stock option grant?

Balthrop received 49,579 stock options with an exercise price of $1.13 per share. These options are exercisable into an equal number of MaxCyte common shares and are scheduled to expire on June 16, 2036, if not exercised earlier.

When do Patrick J. Balthrop’s MaxCyte RSUs vest?

The 30,421 restricted stock units granted to Patrick J. Balthrop are scheduled to vest on June 17, 2027. Vesting is subject to his continuous service as a non-employee director with MaxCyte through that vesting date under the company’s equity grant policy.

Are Patrick J. Balthrop’s MXCT equity awards part of a director compensation policy?

Yes. The annual equity grant to Patrick J. Balthrop was made under MaxCyte’s Equity Grant Policy for non-employee directors. This policy provides recurring stock-based compensation to outside directors, aligning their interests with shareholders through RSUs and options.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/22/2026 - 04:24 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BALTHROP PATRICK J

(Last) (First) (Middle)

C/O MAXCYTE, INC.

9713 KEY WEST AVENUE, SUITE 400

(Street)

ROCKVILLE MARYLAND 20850

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MAXCYTE, INC. [ MXCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/17/2026		A		30,421(1)(2)	A	$0	80,998	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.13	06/17/2026		A		49,579		(2)	06/16/2036	Common Stock	49,579	$0	49,579	D

Explanation of Responses:

1. These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

2. This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 17, 2027, subject to the reporting person's continuous service as of such vesting date.

	/s/ Maher Masoud, Attorney-in-Fact	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)